30th Dec |
Update on Omni Innovation Investment |
28th Dec |
RGP: Refresh Invests in Technology Company |
23rd Dec |
Appendix 3B |
23rd Dec |
Prospectus |
23rd Dec |
Reinstatement to Official Quotation |
23rd Dec |
$1.6m Placement for Omni Innovation Investment |
22nd Dec |
Net Tangible Asset Backing |
14th Dec |
Withdrawal of Entitlement Issue |
14th Dec |
Suspension from Official Quotation |
12th Dec |
Trading Halt |
9th Dec |
Notification of Rights Issue Shortfall |
2nd Dec |
Omni Innovation Market Update |
25th Nov |
Rights Issue Offer Document |
22nd Nov |
Results of Meeting |
22nd Nov |
Becoming a Substantial Holder |
21st Nov |
Omni Innovation secures UK Distribution Deal |
18th Nov |
Letter to Shareholders |
16th Nov |
Appendix 3B |
16th Nov |
Appendix 3B and Cleansing Notice |
16th Nov |
Non-Renounceable Rights Offer |
16th Nov |
Letter to Optionholders |
14th Nov |
Net Tangible Asset Backing |
10th Nov |
Reinstatement to Official Quotation |
10th Nov |
Placement to Chinese Pharmaceutical and Investment Group |
3rd Nov |
Voluntary Suspension |
1st Nov |
Trading Halt |
1st Nov |
Appendix 4C - Quarterly |
1st Nov |
Appendix 4C - Quarterly |
21st Oct |
Annual Report to Shareholders |
21st Oct |
Notice of Annual General Meeting/Proxy Form |
21st Oct |
Appendix 4G and Corporate Governance Statement |
14th Oct |
Net Tangible Asset Backing |
13th Oct |
EVE Investments Webcast on Omniblend Innovation |
30th Sep |
Extension of Omniblend Innovation Tranche 2 Settlement |
21st Sep |
New Study- GlucoControl Improves Long-Term Glycaemic Control |
14th Sep |
Update on Omniblend Innovation |
9th Sep |
Net Tangible Asset Backing |
1st Sep |
Appendix 4E and Full Year Statutory Accounts |
24th Aug |
Omniblend Innovation Enters into US Representation Deal |
12th Aug |
Net Tangible Asset Backing |
27th Jul |
Appendix 4C - Quarterly |
14th Jul |
Net Tangible Asset Backing |
12th Jul |
Omniblend Innovation Appoints Director of Sales & Marketing |
8th Jul |
GlucoControl for type 2 diabetes named Product of the Month |
5th Jul |
GlucoControl Momentum |
10th Jun |
Net Tangible Asset Backing |
31st May |
Appendix 3B and Change of Director's Interest Notice x 3 |
31st May |
Results of Meeting |
13th May |
Net Tangible Asset Backing |
12th May |
Exclusive Engagement Signed with OHC for Scandinavia |
6th May |
GlucoControl Pre-Meal Drink Launched |
3rd May |
Appendix 3B |
29th Apr |
Notice of General Meeting/Proxy Form |
26th Apr |
Appendix 4C - Quarterly |
22nd Apr |
Omniblend Innovation Transaction Completed |
15th Apr |
Net Tangible Asset Backing |
1st Apr |
Extension of Omniblend Innovation Tranche 2 Settlement |
1st Apr |
Change in Substantial Holding |
31st Mar |
Med-Tech Executive Joins EVE Board |
21st Mar |
Completion of $1.85M Non-Renounceable Rights Issue |
4th Mar |
Net Tangible Asset Backing |
1st Mar |
Half Yearly Report and Accounts |
25th Feb |
GlucoControl Product Manufacturing Commences |
22nd Feb |
Letter to Shareholders |
18th Feb |
Fully Underwritten Rights Issue |
18th Feb |
Prospectus |
18th Feb |
Appendix 3B |
18th Feb |
Letter to Optionholders |
15th Feb |
Net Tangible Asset Backing |
3rd Feb |
Investor Presentation - Omniblend Innovation Acquisition |
2nd Feb |
Shareholder Update |
29th Jan |
Appendix 4C - Quarterly |
13th Jan |
Net Tangible Asset Backing |
12th Jan |
Change in Substantial Holding |
4th Jan |
Change of Director's Interest Notice x 2 |
4th Jan |
Appendix 3B |